Global Choroidal Neovascularization Market (2020 to 2025) - Industry Trends, Share, Size, Growth, Opportunity and Forecast - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Choroidal Neovascularization Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

The global choroidal neovascularization market grew at a CAGR of around 8% during 2014-2019. Looking forward, the publisher expects the global choroidal neovascularization market to exhibit moderate growth during the next five years.

Choroidal neovascularization (CNV) refers to the creation of new blood vessels in the choroid layer of the eyes affecting the Bruch's membrane and retinal pigment epithelium (RPE). Its symptoms include lipid exudation, subretinal blood and fluid, and distortion, waviness and black spots in the central vision. At present, a combination of procedures, such as fluorescein angiography (FA), indocyanine green (ICG) angiography and optical coherence tomography (OCT) scanning, are utilized for diagnosing CNV. As per the results, doctors then prescribe anti-vascular endothelial growth factor (VEGF) drugs, thermal laser treatment and photodynamic therapy (PDT), to prevent the growth of the blood vessels.

The market is experiencing growth on account of the rising prevalence of age-related macular degeneration (ARMD), ocular histoplasmosis, pathologic myopia, angioid streaks, choroidal tears and inflammatory diseases of the choroid and retina. Moreover, the increasing geriatric population, which is more vulnerable to serious health conditions, is acting as another key factor bolstering the market growth. Furthermore, the growing adoption of combination drugs, along with the introduction of long-lasting anti-VEGF drugs, is propelling the demand for CNV treatments worldwide. Other factors, such as improving healthcare infrastructure and the increasing investments in research and development (R&D) activities, are also contributing to the growth of the market.

However, with the spread of the coronavirus disease (COVID-19), the healthcare systems of various countries have become overburdened. Consequently, doctors are focusing on patient selection, safe injection techniques and proper sterilization to prevent the risk of contracting and transmitting the disease. In a non-emergency case, they are either rescheduling and postponing the follow-up appointments or providing remote monitoring solutions using telehealth to patients with severe conditions.

Companies Mentioned

• Bausch Health Companies Inc.
• Bayer AG
• Gilead Sciences Inc.
• Hoffmann-La Roche Ltd.
• MaaT Pharma
• Novartis AG
• Pfizer Inc.
• Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
• Regeneron Pharmaceuticals Inc.
• Sanwa Kagaku Kenkyusho Co. Ltd. (Suzuken Co. Ltd.).

Key Questions Answered in This Report:

• How has the global choroidal neovascularization market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global choroidal neovascularization market?
• What are the key regional markets?
• What is the breakup of the market based on the product type?
• What is the breakup of the market based on the type of diagnosis?
• What is the breakup of the market based on the treatment type?
• What is the breakup of the market based on the application?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global choroidal neovascularization market and who are the key players?
• What is the degree of competition in the industry?

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global Choroidal Neovascularization Market

5.1 Market Overview

5.2 Market Performance

5.3 Impact of COVID-19

5.4 Market Forecast

6 Market Breakup by Product Type

6.1 Intravenous

6.1.1 Market Trends

6.1.2 Market Forecast

6.2 Intravitreal

6.2.1 Market Trends

6.2.2 Market Forecast

7 Market Breakup by Type of Diagnosis

7.1 Fluorescein Angiography (FA)

7.1.1 Market Trends

7.1.2 Market Forecast

7.2 Indocyanine Green (ICG) Angiography

7.2.1 Market Trends

7.2.2 Market Forecast

7.3 Spectral Domain Optical Coherence Tomography (OCT)

7.3.1 Market Trends

7.3.2 Market Forecast

7.4 Others

7.4.1 Market Trends

7.4.2 Market Forecast

8 Market Breakup by Treatment Type

8.1 Angiogenesis Inhibitors Injection

8.1.1 Market Trends

8.1.2 Market Forecast

8.2 Photodynamic Therapy

8.2.1 Market Trends

8.2.2 Market Forecast

8.3 Laser Photocoagulation

8.3.1 Market Trends

8.3.2 Market Forecast

8.4 Low-dose Radiation Therapy

8.4.1 Market Trends

8.4.2 Market Forecast

8.5 Surgery

8.5.1 Market Trends

8.5.2 Market Forecast

9 Market Breakup by Application

9.1 Extreme Myopia

9.1.1 Market Trends

9.1.2 Market Forecast

9.2 Malignant Myopic Degeneration

9.2.1 Market Trends

9.2.2 Market Forecast

9.3 Age-Related Developments

9.3.1 Market Trends

9.3.2 Market Forecast

10 Market Breakup by Region

10.1 North America

10.2 Asia Pacific

10.3 Europe

10.4 Latin America

10.5 Middle East and Africa

11 SWOT Analysis

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure

15.2 Key Players

15.3 Profiles of Key Players

For more information about this report visit https://www.researchandmarkets.com/r/uk5etd